And Anavex will surely have to explain during their presentation why its cognitive findings in PDD relate to AD. This explanation will be based on asserting a common MOA in both dementias and that will be considered a very ambitious claim. AVXL has to come with the receipts, and I am sure they will have them.
Friday 6 November 2020 we will hear detailed results regarding the Phase 2 Clinical Trial Evaluating ANAVEX®2-73 (blarcamesine) in Parkinson’s Disease Dementia
Clinically meaningful, dose-dependent, and statistically significant improvements in the Cognitive Drug Research (CDR) computerized assessment system analysis
Cognitive Drug Research (CDR) Computerized Assessment System Continuity of Attention (Time Frame: 14 weeks ) Change from Baseline to End of Treatment in Continuity of Attention as measured by Cognitive Drug Research (CDR) Computerized Assessment System Continuity of Attention test
Number of participants with treatment-related adverse events as assessed by CTCAE v4.0 ( Time Frame: 14 weeks }Assess the safety and tolerability of ANAVEX2-73 compared to placebo
Secondary Outcome Measures:
MDS-UPDRS Part III Total Score (Motor Scores) [ Time Frame: 14 weeks ] Change from baseline to End of Treatment as measured by MDS-UPDRS Part III Total Score (Motor Scores)
SDS-CL-25 [ Time Frame: 14 weeks ] Incidence of sleep disorders symptoms (SDS-CL-25)esine-in-parkinsons-disease-dementia/
News 
Market Data 
Discover 
